

<p style="text-align: center;"><b>Form 5500</b></p> <p style="font-size: small;">Department of the Treasury Internal Revenue Service</p> <hr/> <p style="font-size: small;">Department of Labor Employee Benefits Security Administration</p> <hr/> <p style="font-size: x-small;">Pension Benefit Guaranty Corporation</p>	<p><b>Annual Return/Report of Employee Benefit Plan</b></p> <p style="font-size: small;">This form is required to be filed for employee benefit plans under sections 104 and 4065 of the Employee Retirement Income Security Act of 1974 (ERISA) and sections 6057(b) and 6058(a) of the Internal Revenue Code (the Code).</p> <p>▶ <b>Complete all entries in accordance with the instructions to the Form 5500.</b></p>	<p style="font-size: x-small;">OMB Nos. 1210-0110 1210-0089</p> <hr/> <p style="font-size: large; font-weight: bold;">2023</p> <hr/> <p style="font-weight: bold;">This Form is Open to Public Inspection</p>
---	---	---

**Part I Annual Report Identification Information**  
 For calendar plan year 2023 or fiscal plan year beginning 01/01/2023 and ending 12/31/2023

**A** This return/report is for:  a multiemployer plan  a multiple-employer plan (Filers checking this box must provide participating employer information in accordance with the form instructions.)

a single-employer plan  a DFE (specify) \_\_\_\_\_

**B** This return/report is:  the first return/report  the final return/report

an amended return/report  a short plan year return/report (less than 12 months)

**C** If the plan is a collectively-bargained plan, check here. . . . . ▶

**D** Check box if filing under:  Form 5558  automatic extension  the DFVC program

special extension (enter description)

**E** If this is a retroactively adopted plan permitted by SECURE Act section 201, check here. . . . . ▶

**Part II Basic Plan Information—enter all requested information**

<p><b>1a</b> Name of plan <u>ASTRAZENECA DEFINED BENEFIT PENSION PLAN</u></p>	<p><b>1b</b> Three-digit plan number (PN) ▶ <u>001</u></p>
<p><b>2a</b> Plan sponsor's name (employer, if for a single-employer plan) Mailing address (include room, apt., suite no. and street, or P.O. Box) City or town, state or province, country, and ZIP or foreign postal code (if foreign, see instructions) <u>ASTRAZENECA PHARMACEUTICALS LP</u></p> <p><u>PO BOX 15437</u> <u>WILMINGTON, DE 19850-5437</u></p>	<p><b>1c</b> Effective date of plan <u>01/01/1976</u></p> <p><b>2b</b> Employer Identification Number (EIN) <u>23-2967016</u></p> <p><b>2c</b> Plan Sponsor's telephone number <u>302-886-3000</u></p> <p><b>2d</b> Business code (see instructions) <u>325100</u></p>

**Caution: A penalty for the late or incomplete filing of this return/report will be assessed unless reasonable cause is established.**

Under penalties of perjury and other penalties set forth in the instructions, I declare that I have examined this return/report, including accompanying schedules, statements and attachments, as well as the electronic version of this return/report, and to the best of my knowledge and belief, it is true, correct, and complete.

<b>SIGN HERE</b>	Filed with authorized/valid electronic signature.	10/15/2024	JANET LEVENT
	Signature of plan administrator	Date	Enter name of individual signing as plan administrator
<b>SIGN HERE</b>	Filed with authorized/valid electronic signature.	10/15/2024	KEVIN DURNING
	Signature of employer/plan sponsor	Date	Enter name of individual signing as employer or plan sponsor
<b>SIGN HERE</b>			
	Signature of DFE	Date	Enter name of individual signing as DFE

<b>3a</b> Plan administrator's name and address <input type="checkbox"/> Same as Plan Sponsor  ASTRAZENECA ADMINISTRATION COMMITTEE  1800 CONCORD PIKE WILMINGTON, DE 19850-5437		<b>3b</b> Administrator's EIN 23-2967016	
		<b>3c</b> Administrator's telephone number 302-886-3000	
<b>4</b> If the name and/or EIN of the plan sponsor or the plan name has changed since the last return/report filed for this plan, enter the plan sponsor's name, EIN, the plan name and the plan number from the last return/report: <b>a</b> Sponsor's name <b>c</b> Plan Name		<b>4b</b> EIN	
		<b>4d</b> PN	
<b>5</b> Total number of participants at the beginning of the plan year		<b>5</b>	5825
<b>6</b> Number of participants as of the end of the plan year unless otherwise stated (welfare plans complete only lines <b>6a(1)</b> , <b>6a(2)</b> , <b>6b</b> , <b>6c</b> , and <b>6d</b> ). <b>a(1)</b> Total number of active participants at the beginning of the plan year ..... <b>a(2)</b> Total number of active participants at the end of the plan year ..... <b>b</b> Retired or separated participants receiving benefits ..... <b>c</b> Other retired or separated participants entitled to future benefits ..... <b>d</b> Subtotal. Add lines <b>6a(2)</b> , <b>6b</b> , and <b>6c</b> . ..... <b>e</b> Deceased participants whose beneficiaries are receiving or are entitled to receive benefits ..... <b>f</b> Total. Add lines <b>6d</b> and <b>6e</b> . ..... <b>g(1)</b> Number of participants with account balances as of the beginning of the plan year (only defined contribution plans complete this item) ..... <b>g(2)</b> Number of participants with account balances as of the end of the plan year (only defined contribution plans complete this item) ..... <b>h</b> Number of participants who terminated employment during the plan year with accrued benefits that were less than 100% vested.....			
		<b>6a(1)</b>	478
		<b>6a(2)</b>	0
		<b>6b</b>	0
		<b>6c</b>	0
		<b>6d</b>	0
		<b>6e</b>	0
		<b>6f</b>	0
		<b>6g(1)</b>	
		<b>6g(2)</b>	
		<b>6h</b>	0
<b>7</b> Enter the total number of employers obligated to contribute to the plan (only multiemployer plans complete this item).....		<b>7</b>	

**8a** If the plan provides pension benefits, enter the applicable pension feature codes from the List of Plan Characteristics Codes in the instructions:  
1A 3F 3H 3J 1I

**b** If the plan provides welfare benefits, enter the applicable welfare feature codes from the List of Plan Characteristics Codes in the instructions:

<b>9a</b> Plan funding arrangement (check all that apply) (1) <input type="checkbox"/> Insurance (2) <input type="checkbox"/> Code section 412(e)(3) insurance contracts (3) <input checked="" type="checkbox"/> Trust (4) <input type="checkbox"/> General assets of the sponsor	<b>9b</b> Plan benefit arrangement (check all that apply) (1) <input type="checkbox"/> Insurance (2) <input type="checkbox"/> Code section 412(e)(3) insurance contracts (3) <input checked="" type="checkbox"/> Trust (4) <input type="checkbox"/> General assets of the sponsor
---	---

**10** Check all applicable boxes in 10a and 10b to indicate which schedules are attached, and, where indicated, enter the number attached. (See instructions)

<b>a Pension Schedules</b> (1) <input checked="" type="checkbox"/> <b>R</b> (Retirement Plan Information) (2) <input type="checkbox"/> <b>MB</b> (Multiemployer Defined Benefit Plan and Certain Money Purchase Plan Actuarial Information) - signed by the plan actuary (3) <input type="checkbox"/> <b>SB</b> (Single-Employer Defined Benefit Plan Actuarial Information) - signed by the plan actuary (4) <input type="checkbox"/> <b>DCG</b> (Individual Plan Information) – Number Attached _____ (5) <input type="checkbox"/> <b>MEP</b> (Multiple-Employer Retirement Plan Information)	<b>b General Schedules</b> (1) <input checked="" type="checkbox"/> <b>H</b> (Financial Information) (2) <input type="checkbox"/> <b>I</b> (Financial Information – Small Plan) (3) <input type="checkbox"/> <b>A</b> (Insurance Information) – Number Attached <u>0</u> (4) <input type="checkbox"/> <b>C</b> (Service Provider Information) (5) <input checked="" type="checkbox"/> <b>D</b> (DFE/Participating Plan Information) (6) <input type="checkbox"/> <b>G</b> (Financial Transaction Schedules)
--	--

---

**Part III Form M-1 Compliance Information (to be completed by welfare benefit plans)**

---

**11a** If the plan provides welfare benefits, was the plan subject to the Form M-1 filing requirements during the plan year? (See instructions and 29 CFR 2520.101-2.) .....  Yes  No

If "Yes" is checked, complete lines 11b and 11c.

---

**11b** Is the plan currently in compliance with the Form M-1 filing requirements? (See instructions and 29 CFR 2520.101-2.) .....  Yes  No

**11c** Enter the Receipt Confirmation Code for the 2023 Form M-1 annual report. If the plan was not required to file the 2023 Form M-1 annual report, enter the Receipt Confirmation Code for the most recent Form M-1 that was required to be filed under the Form M-1 filing requirements. (Failure to enter a valid Receipt Confirmation Code will subject the Form 5500 filing to rejection as incomplete.)

Receipt Confirmation Code \_\_\_\_\_

---

<b>SCHEDULE D</b> <b>(Form 5500)</b>  <small>Department of the Treasury Internal Revenue Service</small>  <small>Department of Labor Employee Benefits Security Administration</small>	<b>DFE/Participating Plan Information</b>  This schedule is required to be filed under section 104 of the Employee Retirement Income Security Act of 1974 (ERISA).  <b>▶ File as an attachment to Form 5500.</b>	<small>OMB No. 1210-0110</small>  <b>2023</b>  <b>This Form is Open to Public Inspection.</b>
---	--	---

For calendar plan year 2023 or fiscal plan year beginning 01/01/2023 and ending 12/31/2023

<b>A</b> Name of plan <u>ASTRAZENECA DEFINED BENEFIT PENSION PLAN</u>	<b>B</b> Three-digit plan number (PN)	<u>001</u>
<b>C</b> Plan or DFE sponsor's name as shown on line 2a of Form 5500 <u>ASTRAZENECA PHARMACEUTICALS LP</u>	<b>D</b> Employer Identification Number (EIN) <u>23-2967016</u>	

<b>Part I</b>	<b>Information on interests in MTIAs, CCTs, PSAs, and 103-12 IEs (to be completed by plans and DFEs)</b> (Complete as many entries as needed to report all interests in DFEs)
---------------	--

<b>a</b> Name of MTIA, CCT, PSA, or 103-12 IE:	<u>ASTRAZENECA TRUST FOR DB PENS PLANS</u>		
<b>b</b> Name of sponsor of entity listed in (a):	<u>ASTRAZENECA PHARMACEUTICALS LP</u>		
<b>c</b> EIN-PN	<b>d</b> Entity code	<b>e</b> Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)	<u>0</u>
<u>13-6052299-001</u>	<u>M</u>		

  

<b>a</b> Name of MTIA, CCT, PSA, or 103-12 IE:			
<b>b</b> Name of sponsor of entity listed in (a):			
<b>c</b> EIN-PN	<b>d</b> Entity code	<b>e</b> Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)	

  

<b>a</b> Name of MTIA, CCT, PSA, or 103-12 IE:			
<b>b</b> Name of sponsor of entity listed in (a):			
<b>c</b> EIN-PN	<b>d</b> Entity code	<b>e</b> Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)	

  

<b>a</b> Name of MTIA, CCT, PSA, or 103-12 IE:			
<b>b</b> Name of sponsor of entity listed in (a):			
<b>c</b> EIN-PN	<b>d</b> Entity code	<b>e</b> Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)	

  

<b>a</b> Name of MTIA, CCT, PSA, or 103-12 IE:			
<b>b</b> Name of sponsor of entity listed in (a):			
<b>c</b> EIN-PN	<b>d</b> Entity code	<b>e</b> Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)	

  

<b>a</b> Name of MTIA, CCT, PSA, or 103-12 IE:			
<b>b</b> Name of sponsor of entity listed in (a):			
<b>c</b> EIN-PN	<b>d</b> Entity code	<b>e</b> Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)	

  

<b>a</b> Name of MTIA, CCT, PSA, or 103-12 IE:			
<b>b</b> Name of sponsor of entity listed in (a):			
<b>c</b> EIN-PN	<b>d</b> Entity code	<b>e</b> Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)	

**a** Name of MTIA, CCT, PSA, or 103-12 IE:

**b** Name of sponsor of entity listed in (a):

**c** EIN-PN

**d** Entity code

**e** Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)

**a** Name of MTIA, CCT, PSA, or 103-12 IE:

**b** Name of sponsor of entity listed in (a):

**c** EIN-PN

**d** Entity code

**e** Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)

**a** Name of MTIA, CCT, PSA, or 103-12 IE:

**b** Name of sponsor of entity listed in (a):

**c** EIN-PN

**d** Entity code

**e** Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)

**a** Name of MTIA, CCT, PSA, or 103-12 IE:

**b** Name of sponsor of entity listed in (a):

**c** EIN-PN

**d** Entity code

**e** Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)

**a** Name of MTIA, CCT, PSA, or 103-12 IE:

**b** Name of sponsor of entity listed in (a):

**c** EIN-PN

**d** Entity code

**e** Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)

**a** Name of MTIA, CCT, PSA, or 103-12 IE:

**b** Name of sponsor of entity listed in (a):

**c** EIN-PN

**d** Entity code

**e** Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)

**a** Name of MTIA, CCT, PSA, or 103-12 IE:

**b** Name of sponsor of entity listed in (a):

**c** EIN-PN

**d** Entity code

**e** Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)

**a** Name of MTIA, CCT, PSA, or 103-12 IE:

**b** Name of sponsor of entity listed in (a):

**c** EIN-PN

**d** Entity code

**e** Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)

**a** Name of MTIA, CCT, PSA, or 103-12 IE:

**b** Name of sponsor of entity listed in (a):

**c** EIN-PN

**d** Entity code

**e** Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)

**a** Name of MTIA, CCT, PSA, or 103-12 IE:

**b** Name of sponsor of entity listed in (a):

**c** EIN-PN

**d** Entity code

**e** Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)

**Part II Information on Participating Plans (to be completed by DFEs, other than DCGs)**

(Complete as many entries as needed to report all participating plans. DCGs must report each participating plan using Schedule DCG.)

**a** Plan name

**b** Name of plan sponsor

**c** EIN-PN

**a** Plan name

**b** Name of plan sponsor

**c** EIN-PN

**a** Plan name

**b** Name of plan sponsor

**c** EIN-PN

**a** Plan name

**b** Name of plan sponsor

**c** EIN-PN

**a** Plan name

**b** Name of plan sponsor

**c** EIN-PN

**a** Plan name

**b** Name of plan sponsor

**c** EIN-PN

**a** Plan name

**b** Name of plan sponsor

**c** EIN-PN

**a** Plan name

**b** Name of plan sponsor

**c** EIN-PN

**a** Plan name

**b** Name of plan sponsor

**c** EIN-PN

**a** Plan name

**b** Name of plan sponsor

**c** EIN-PN

**a** Plan name

**b** Name of plan sponsor

**c** EIN-PN

**a** Plan name

**b** Name of plan sponsor

**c** EIN-PN

**SCHEDULE H  
(Form 5500)**

Department of the Treasury  
Internal Revenue Service

Department of Labor  
Employee Benefits Security Administration

Pension Benefit Guaranty Corporation

**Financial Information**

This schedule is required to be filed under section 104 of the Employee Retirement Income Security Act of 1974 (ERISA), and section 6058(a) of the Internal Revenue Code (the Code).

► **File as an attachment to Form 5500.**

OMB No. 1210-0110

**2023**

**This Form is Open to Public Inspection**

For calendar plan year 2023 or fiscal plan year beginning **01/01/2023** and ending **12/31/2023**

<b>A</b> Name of plan ASTRAZENECA DEFINED BENEFIT PENSION PLAN		<b>B</b> Three-digit plan number (PN) ►	001
<b>C</b> Plan sponsor's name as shown on line 2a of Form 5500 ASTRAZENECA PHARMACEUTICALS LP		<b>D</b> Employer Identification Number (EIN) 23-2967016	

**Part I Asset and Liability Statement**

**1** Current value of plan assets and liabilities at the beginning and end of the plan year. Combine the value of plan assets held in more than one trust. Report the value of the plan's interest in a commingled fund containing the assets of more than one plan on a line-by-line basis unless the value is reportable on lines 1c(9) through 1c(14). Do not enter the value of that portion of an insurance contract which guarantees, during this plan year, to pay a specific dollar benefit at a future date. **Round off amounts to the nearest dollar.** MTIAs, CCTs, PSAs, and 103-12 IEs do not complete lines 1b(1), 1b(2), 1c(8), 1g, 1h, and 1i. CCTs, PSAs, and 103-12 IEs also do not complete lines 1d and 1e. See instructions.

Assets	(a) Beginning of Year	(b) End of Year
<b>a</b> Total noninterest-bearing cash .....	<b>1a</b>	
<b>b</b> Receivables (less allowance for doubtful accounts):		
<b>(1)</b> Employer contributions .....	<b>1b(1)</b>	
<b>(2)</b> Participant contributions .....	<b>1b(2)</b>	
<b>(3)</b> Other .....	<b>1b(3)</b>	
<b>c</b> General investments:		
<b>(1)</b> Interest-bearing cash (include money market accounts & certificates of deposit) .....	<b>1c(1)</b>	
<b>(2)</b> U.S. Government securities .....	<b>1c(2)</b>	
<b>(3)</b> Corporate debt instruments (other than employer securities):		
<b>(A)</b> Preferred .....	<b>1c(3)(A)</b>	
<b>(B)</b> All other .....	<b>1c(3)(B)</b>	
<b>(4)</b> Corporate stocks (other than employer securities):		
<b>(A)</b> Preferred .....	<b>1c(4)(A)</b>	
<b>(B)</b> Common .....	<b>1c(4)(B)</b>	
<b>(5)</b> Partnership/joint venture interests .....	<b>1c(5)</b>	
<b>(6)</b> Real estate (other than employer real property) .....	<b>1c(6)</b>	
<b>(7)</b> Loans (other than to participants) .....	<b>1c(7)</b>	
<b>(8)</b> Participant loans .....	<b>1c(8)</b>	
<b>(9)</b> Value of interest in common/collective trusts .....	<b>1c(9)</b>	
<b>(10)</b> Value of interest in pooled separate accounts .....	<b>1c(10)</b>	
<b>(11)</b> Value of interest in master trust investment accounts .....	<b>1c(11)</b>	0
<b>(12)</b> Value of interest in 103-12 investment entities .....	<b>1c(12)</b>	
<b>(13)</b> Value of interest in registered investment companies (e.g., mutual funds) .....	<b>1c(13)</b>	
<b>(14)</b> Value of funds held in insurance company general account (unallocated contracts) .....	<b>1c(14)</b>	
<b>(15)</b> Other .....	<b>1c(15)</b>	

1d Employer-related investments:		(a) Beginning of Year	(b) End of Year
(1) Employer securities .....	1d(1)		
(2) Employer real property .....	1d(2)		
e Buildings and other property used in plan operation .....	1e		
f Total assets (add all amounts in lines 1a through 1e) .....	1f	832761000	0
<b>Liabilities</b>			
g Benefit claims payable .....	1g		
h Operating payables .....	1h		
i Acquisition indebtedness .....	1i		
j Other liabilities .....	1j		
k Total liabilities (add all amounts in lines 1g through 1j) .....	1k	0	0
<b>Net Assets</b>			
l Net assets (subtract line 1k from line 1f) .....	1l	832761000	0

**Part II Income and Expense Statement**

2 Plan income, expenses, and changes in net assets for the year. Include all income and expenses of the plan, including any trust(s) or separately maintained fund(s) and any payments/receipts to/from insurance carriers. Round off amounts to the nearest dollar. MTIAs, CCTs, PSAs, and 103-12 IEs do not complete lines 2a, 2b(1)(E), 2e, 2f, and 2g.

<b>Income</b>		(a) Amount	(b) Total
<b>a Contributions:</b>			
(1) Received or receivable in cash from: (A) Employers .....	2a(1)(A)	26800000	
(B) Participants .....	2a(1)(B)		
(C) Others (including rollovers) .....	2a(1)(C)		
(2) Noncash contributions .....	2a(2)		
(3) Total contributions. Add lines 2a(1)(A), (B), (C), and line 2a(2) .....	2a(3)		26800000
<b>b Earnings on investments:</b>			
(1) Interest:			
(A) Interest-bearing cash (including money market accounts and certificates of deposit) .....	2b(1)(A)		
(B) U.S. Government securities .....	2b(1)(B)		
(C) Corporate debt instruments .....	2b(1)(C)		
(D) Loans (other than to participants) .....	2b(1)(D)		
(E) Participant loans .....	2b(1)(E)		
(F) Other .....	2b(1)(F)		
(G) Total interest. Add lines 2b(1)(A) through (F) .....	2b(1)(G)		0
(2) Dividends:			
(A) Preferred stock .....	2b(2)(A)		
(B) Common stock .....	2b(2)(B)		
(C) Registered investment company shares (e.g. mutual funds) .....	2b(2)(C)		
(D) Total dividends. Add lines 2b(2)(A), (B), and (C) .....	2b(2)(D)		0
(3) Rents .....	2b(3)		
(4) Net gain (loss) on sale of assets:			
(A) Aggregate proceeds .....	2b(4)(A)		
(B) Aggregate carrying amount (see instructions) .....	2b(4)(B)		
(C) Subtract line 2b(4)(B) from line 2b(4)(A) and enter result .....	2b(4)(C)		
(5) Unrealized appreciation (depreciation) of assets:			
(A) Real estate .....	2b(5)(A)		
(B) Other .....	2b(5)(B)		
(C) Total unrealized appreciation of assets. Add lines 2b(5)(A) and (B) .....	2b(5)(C)		

		(a) Amount	(b) Total
(6) Net investment gain (loss) from common/collective trusts.....	<b>2b(6)</b>		
(7) Net investment gain (loss) from pooled separate accounts.....	<b>2b(7)</b>		
(8) Net investment gain (loss) from master trust investment accounts.....	<b>2b(8)</b>		22249000
(9) Net investment gain (loss) from 103-12 investment entities.....	<b>2b(9)</b>		
(10) Net investment gain (loss) from registered investment companies (e.g., mutual funds) .....	<b>2b(10)</b>		
<b>c</b> Other income .....	<b>2c</b>		
<b>d</b> Total income. Add all <b>income</b> amounts in column (b) and enter total .....	<b>2d</b>		49049000

**Expenses**

<b>e</b> Benefit payment and payments to provide benefits:			
(1) Directly to participants or beneficiaries, including direct rollovers .....	<b>2e(1)</b>	182436000	
(2) To insurance carriers for the provision of benefits.....	<b>2e(2)</b>		
(3) Other.....	<b>2e(3)</b>	697241000	
(4) Total benefit payments. Add lines <b>2e(1)</b> through <b>(3)</b> .....	<b>2e(4)</b>		879677000
<b>f</b> Corrective distributions (see instructions).....	<b>2f</b>		
<b>g</b> Certain deemed distributions of participant loans (see instructions) .....	<b>2g</b>		
<b>h</b> Interest expense .....	<b>2h</b>		
<b>i</b> Administrative expenses:			
(1) Salaries and allowances.....	<b>2i(1)</b>		
(2) Contract administrator fees.....	<b>2i(2)</b>		
(3) Recordkeeping fees.....	<b>2i(3)</b>		
(4) IQPA audit fees.....	<b>2i(4)</b>		
(5) Investment advisory and investment management fees .....	<b>2i(5)</b>		
(6) Bank or trust company trustee/custodial fees .....	<b>2i(6)</b>		
(7) Actuarial fees .....	<b>2i(7)</b>		
(8) Legal fees .....	<b>2i(8)</b>		
(9) Valuation/appraisal fees .....	<b>2i(9)</b>		
(10) Other trustee fees and expenses .....	<b>2i(10)</b>		
(11) Other expenses .....	<b>2i(11)</b>		
(12) Total administrative expenses. Add lines <b>2i(1)</b> through <b>(11)</b> .....	<b>2i(12)</b>		0
<b>j</b> Total expenses. Add all <b>expense</b> amounts in column (b) and enter total .....	<b>2j</b>		879677000

**Net Income and Reconciliation**

<b>k</b> Net income (loss). Subtract line <b>2j</b> from line <b>2d</b> .....	<b>2k</b>		-830628000
<b>l</b> Transfers of assets:			
(1) To this plan .....	<b>2l(1)</b>		
(2) From this plan .....	<b>2l(2)</b>		2133000

**Part III Accountant's Opinion**

**3** Complete lines 3a through 3c if the opinion of an independent qualified public accountant is attached to this Form 5500. Complete line 3d if an opinion is not attached.

**a** The attached opinion of an independent qualified public accountant for this plan is (see instructions):

(1)  Unmodified (2)  Qualified (3)  Disclaimer (4)  Adverse

**b** Check the appropriate box(es) to indicate whether the IQPA performed an ERISA section 103(a)(3)(C) audit. Check both boxes (1) and (2) if the audit was performed pursuant to both 29 CFR 2520.103-8 and 29 CFR 2520.103-12(d). Check box (3) if pursuant to neither.

(1)  DOL Regulation 2520.103-8 (2)  DOL Regulation 2520.103-12(d) (3)  neither DOL Regulation 2520.103-8 nor DOL Regulation 2520.103-12(d).

**c** Enter the name and EIN of the accountant (or accounting firm) below:

(1) Name: PRICEWATERHOUSECOOPERS LLP

(2) EIN: 13-4008324

**d** The opinion of an independent qualified public accountant is **not attached** as part of Schedule H because:

(1)  This form is filed for a CCT, PSA, DCG or MTIA. (2)  It will be attached to the next Form 5500 pursuant to 29 CFR 2520.104-50.

**Part IV Compliance Questions**

**4** CCTs and PSAs do not complete Part IV. MTIAs, 103-12 IEs, and GIAs do not complete lines 4a, 4e, 4f, 4g, 4h, 4k, 4m, 4n, or 5. 103-12 IEs also do not complete lines 4j and 4l. MTIAs also do not complete line 4l. DCGs do not complete lines 4e, 4f, 4k, 4l, and 5, and DCGs generally complete the rest of Part IV collectively for all plans in the DCG, except as otherwise provided (see instructions).

During the plan year:

	Yes	No	Amount
<b>a</b> Was there a failure to transmit to the plan any participant contributions within the time period described in 29 CFR 2510.3-102? Continue to answer "Yes" for any prior year failures until fully corrected. (See instructions and DOL's Voluntary Fiduciary Correction Program.)		X	
<b>b</b> Were any loans by the plan or fixed income obligations due the plan in default as of the close of the plan year or classified during the year as uncollectible? Disregard participant loans secured by participant's account balance. (Attach Schedule G (Form 5500) Part I if "Yes" is checked.)		X	
<b>c</b> Were any leases to which the plan was a party in default or classified during the year as uncollectible? (Attach Schedule G (Form 5500) Part II if "Yes" is checked.)		X	
<b>d</b> Were there any nonexempt transactions with any party-in-interest? (Do not include transactions reported on line 4a. Attach Schedule G (Form 5500) Part III if "Yes" is checked.)		X	
<b>e</b> Was this plan covered by a fidelity bond?	X		5000000
<b>f</b> Did the plan have a loss, whether or not reimbursed by the plan's fidelity bond, that was caused by fraud or dishonesty?		X	
<b>g</b> Did the plan hold any assets whose current value was neither readily determinable on an established market nor set by an independent third party appraiser?		X	
<b>h</b> Did the plan receive any noncash contributions whose value was neither readily determinable on an established market nor set by an independent third party appraiser?		X	
<b>i</b> Did the plan have assets held for investment? (Attach schedule(s) of assets if "Yes" is checked, and see instructions for format requirements.)		X	
<b>j</b> Were any plan transactions or series of transactions in excess of 5% of the current value of plan assets? (Attach schedule of transactions if "Yes" is checked and see instructions for format requirements.)		X	
<b>k</b> Were all the plan assets either distributed to participants or beneficiaries, transferred to another plan, or brought under the control of the PBGC?	X		
<b>l</b> Has the plan failed to provide any benefit when due under the plan?		X	
<b>m</b> If this is an individual account plan, was there a blackout period? (See instructions and 29 CFR 2520.101-3.)			
<b>n</b> If 4m was answered "Yes," check the "Yes" box if you either provided the required notice or one of the exceptions to providing the notice applied under 29 CFR 2520.101-3.			

**5a** Has a resolution to terminate the plan been adopted during the plan year or any prior plan year?  Yes  No  
If "Yes," enter the amount of any plan assets that reverted to the employer this year 1652000.

**5b** If, during this plan year, any assets or liabilities were transferred from this plan to another plan(s), identify the plan(s) to which assets or liabilities were transferred. (See instructions.)

<b>5b(1)</b> Name of plan(s)	<b>5b(2)</b> EIN(s)	<b>5b(3)</b> PN(s)
ASTRAZENECA SAVINGS AND SECURITY PLAN	23-2967016	002

**5c** Was the plan a defined benefit plan covered under the PBGC insurance program at any time during this plan year? (See ERISA section 4021 and instructions.) .....  Yes  No  Not determined

If "Yes" is checked, enter the My PAA confirmation number from the PBGC premium filing for this plan year \_\_\_\_\_.

<b>SCHEDULE R</b> <b>(Form 5500)</b>  <small>Department of the Treasury Internal Revenue Service</small>  <small>Department of Labor Employee Benefits Security Administration</small>  <small>Pension Benefit Guaranty Corporation</small>	<b>Retirement Plan Information</b>  This schedule is required to be filed under sections 104 and 4065 of the Employee Retirement Income Security Act of 1974 (ERISA) and section 6058(a) of the Internal Revenue Code (the Code).  <b>▶ File as an attachment to Form 5500.</b>	<small>OMB No. 1210-0110</small>  <b>2023</b>  <b>This Form is Open to Public Inspection.</b>
--	---	---

For calendar plan year 2023 or fiscal plan year beginning 01/01/2023 and ending 12/31/2023

<b>A</b> Name of plan <u>ASTRAZENECA DEFINED BENEFIT PENSION PLAN</u>	<b>B</b> Three-digit plan number (PN) ▶	<u>001</u>
<b>C</b> Plan sponsor's name as shown on line 2a of Form 5500 <u>ASTRAZENECA PHARMACEUTICALS LP</u>	<b>D</b> Employer Identification Number (EIN) <u>23-2967016</u>	

<b>Part I</b>	<b>Distributions</b>
---------------	----------------------

**All references to distributions relate only to payments of benefits during the plan year.**

<b>1</b> Total value of distributions paid in property other than in cash or the forms of property specified in the instructions.....	1	0
---	---	---

**2** Enter the EIN(s) of payor(s) who paid benefits on behalf of the plan to participants or beneficiaries during the year (if more than two, enter EINs of the two payors who paid the greatest dollar amounts of benefits):  
 EIN(s): 23-2967016

**Profit-sharing plans, ESOPs, and stock bonus plans, skip line 3.**

<b>3</b> Number of participants (living or deceased) whose benefits were distributed in a single sum, during the plan year .....	3	1039
--	---	------

<b>Part II</b>	<b>Funding Information</b> (If the plan is not subject to the minimum funding requirements of section 412 of the Internal Revenue Code or ERISA section 302, skip this Part.)
----------------	---

**4** Is the plan administrator making an election under Code section 412(d)(2) or ERISA section 302(d)(2)? .....  Yes  No  N/A  
**If the plan is a defined benefit plan, go to line 8.**

**5** If a waiver of the minimum funding standard for a prior year is being amortized in this plan year, see instructions and enter the date of the ruling letter granting the waiver. **Date:** Month \_\_\_\_\_ Day \_\_\_\_\_ Year \_\_\_\_\_  
**If you completed line 5, complete lines 3, 9, and 10 of Schedule MB and do not complete the remainder of this schedule.**

<b>6 a</b> Enter the minimum required contribution for this plan year (include any prior year accumulated funding deficiency not waived) .....	6a	
<b>b</b> Enter the amount contributed by the employer to the plan for this plan year .....	6b	
<b>c</b> Subtract the amount in line 6b from the amount in line 6a. Enter the result (enter a minus sign to the left of a negative amount) .....	6c	

**If you completed line 6c, skip lines 8 and 9.**

**7** Will the minimum funding amount reported on line 6c be met by the funding deadline? .....  Yes  No  N/A

**8** If a change in actuarial cost method was made for this plan year pursuant to a revenue procedure or other authority providing automatic approval for the change or a class ruling letter, does the plan sponsor or plan administrator agree with the change? .....  Yes  No  N/A

<b>Part III</b>	<b>Amendments</b>
-----------------	-------------------

**9** If this is a defined benefit pension plan, were any amendments adopted during this plan year that increased or decreased the value of benefits? If yes, check the appropriate box. If no, check the "No" box. ....  Increase  Decrease  Both  No

<b>Part IV</b>	<b>ESOPs</b> (see instructions). If this is not a plan described under section 409(a) or 4975(e)(7) of the Internal Revenue Code, skip this Part.
----------------	---

**10** Were unallocated employer securities or proceeds from the sale of unallocated securities used to repay any exempt loan?.....  Yes  No

**11 a** Does the ESOP hold any preferred stock? .....  Yes  No

**b** If the ESOP has an outstanding exempt loan with the employer as lender, is such loan part of a "back-to-back" loan? (See instructions for definition of "back-to-back" loan.) .....  Yes  No

**12** Does the ESOP hold any stock that is not readily tradable on an established securities market? .....  Yes  No

**Part V Additional Information for Multiemployer Defined Benefit Pension Plans**

**13** Enter the following information for each employer that (1) contributed more than 5% of total contributions to the plan during the plan year or (2) was one of the top-ten highest contributors (measured in dollars). See instructions. Complete as many entries as needed to report all applicable employers.

**a** Name of contributing employer \_\_\_\_\_

**b** EIN \_\_\_\_\_ **c** Dollar amount contributed by employer \_\_\_\_\_

**d** Date collective bargaining agreement expires (If employer contributes under more than one collective bargaining agreement, check box  and see instructions regarding required attachment. Otherwise, enter the applicable date.) Month \_\_\_\_\_ Day \_\_\_\_\_ Year \_\_\_\_\_

**e** Contribution rate information (If more than one rate applies, check this box  and see instructions regarding required attachment. Otherwise, complete lines 13e(1) and 13e(2).)

(1) Contribution rate (in dollars and cents) \_\_\_\_\_

(2) Base unit measure:  Hourly  Weekly  Unit of production  Other (specify): \_\_\_\_\_

**a** Name of contributing employer \_\_\_\_\_

**b** EIN \_\_\_\_\_ **c** Dollar amount contributed by employer \_\_\_\_\_

**d** Date collective bargaining agreement expires (If employer contributes under more than one collective bargaining agreement, check box  and see instructions regarding required attachment. Otherwise, enter the applicable date.) Month \_\_\_\_\_ Day \_\_\_\_\_ Year \_\_\_\_\_

**e** Contribution rate information (If more than one rate applies, check this box  and see instructions regarding required attachment. Otherwise, complete lines 13e(1) and 13e(2).)

(1) Contribution rate (in dollars and cents) \_\_\_\_\_

(2) Base unit measure:  Hourly  Weekly  Unit of production  Other (specify): \_\_\_\_\_

**a** Name of contributing employer \_\_\_\_\_

**b** EIN \_\_\_\_\_ **c** Dollar amount contributed by employer \_\_\_\_\_

**d** Date collective bargaining agreement expires (If employer contributes under more than one collective bargaining agreement, check box  and see instructions regarding required attachment. Otherwise, enter the applicable date.) Month \_\_\_\_\_ Day \_\_\_\_\_ Year \_\_\_\_\_

**e** Contribution rate information (If more than one rate applies, check this box  and see instructions regarding required attachment. Otherwise, complete lines 13e(1) and 13e(2).)

(1) Contribution rate (in dollars and cents) \_\_\_\_\_

(2) Base unit measure:  Hourly  Weekly  Unit of production  Other (specify): \_\_\_\_\_

**a** Name of contributing employer \_\_\_\_\_

**b** EIN \_\_\_\_\_ **c** Dollar amount contributed by employer \_\_\_\_\_

**d** Date collective bargaining agreement expires (If employer contributes under more than one collective bargaining agreement, check box  and see instructions regarding required attachment. Otherwise, enter the applicable date.) Month \_\_\_\_\_ Day \_\_\_\_\_ Year \_\_\_\_\_

**e** Contribution rate information (If more than one rate applies, check this box  and see instructions regarding required attachment. Otherwise, complete lines 13e(1) and 13e(2).)

(1) Contribution rate (in dollars and cents) \_\_\_\_\_

(2) Base unit measure:  Hourly  Weekly  Unit of production  Other (specify): \_\_\_\_\_

**a** Name of contributing employer \_\_\_\_\_

**b** EIN \_\_\_\_\_ **c** Dollar amount contributed by employer \_\_\_\_\_

**d** Date collective bargaining agreement expires (If employer contributes under more than one collective bargaining agreement, check box  and see instructions regarding required attachment. Otherwise, enter the applicable date.) Month \_\_\_\_\_ Day \_\_\_\_\_ Year \_\_\_\_\_

**e** Contribution rate information (If more than one rate applies, check this box  and see instructions regarding required attachment. Otherwise, complete lines 13e(1) and 13e(2).)

(1) Contribution rate (in dollars and cents) \_\_\_\_\_

(2) Base unit measure:  Hourly  Weekly  Unit of production  Other (specify): \_\_\_\_\_

**a** Name of contributing employer \_\_\_\_\_

**b** EIN \_\_\_\_\_ **c** Dollar amount contributed by employer \_\_\_\_\_

**d** Date collective bargaining agreement expires (If employer contributes under more than one collective bargaining agreement, check box  and see instructions regarding required attachment. Otherwise, enter the applicable date.) Month \_\_\_\_\_ Day \_\_\_\_\_ Year \_\_\_\_\_

**e** Contribution rate information (If more than one rate applies, check this box  and see instructions regarding required attachment. Otherwise, complete lines 13e(1) and 13e(2).)

(1) Contribution rate (in dollars and cents) \_\_\_\_\_

(2) Base unit measure:  Hourly  Weekly  Unit of production  Other (specify): \_\_\_\_\_

**14** Enter the number of deferred vested and retired participants (inactive participants), as of the beginning of the plan year, whose contributing employer is no longer making contributions to the plan for:

<b>a</b> The current plan year. Check the box to indicate the counting method used to determine the number of inactive participants: <input type="checkbox"/> last contributing employer <input type="checkbox"/> alternative <input type="checkbox"/> reasonable approximation (see instructions for required attachment) .....	<b>14a</b>	
<b>b</b> The plan year immediately preceding the current plan year. <input type="checkbox"/> Check the box if the number reported is a change from what was previously reported (see instructions for required attachment) .....	<b>14b</b>	
<b>c</b> The second preceding plan year. <input type="checkbox"/> Check the box if the number reported is a change from what was previously reported (see instructions for required attachment).....	<b>14c</b>	

**15** Enter the ratio of the number of participants under the plan on whose behalf no employer had an obligation to make an employer contribution during the current plan year to:

<b>a</b> The corresponding number for the plan year immediately preceding the current plan year .....	<b>15a</b>	
<b>b</b> The corresponding number for the second preceding plan year .....	<b>15b</b>	

**16** Information with respect to any employers who withdrew from the plan during the preceding plan year:

<b>a</b> Enter the number of employers who withdrew during the preceding plan year .....	<b>16a</b>	
<b>b</b> If line 16a is greater than 0, enter the aggregate amount of withdrawal liability assessed or estimated to be assessed against such withdrawn employers .....	<b>16b</b>	

**17** If assets and liabilities from another plan have been transferred to or merged with this plan during the plan year, check box and see instructions regarding supplemental information to be included as an attachment.....

**Part VI Additional Information for Single-Employer and Multiemployer Defined Benefit Pension Plans**

**18** If any liabilities to participants or their beneficiaries under the plan as of the end of the plan year consist (in whole or in part) of liabilities to such participants and beneficiaries under two or more pension plans as of immediately before such plan year, check box and see instructions regarding supplemental information to be included as an attachment.....

**19** If the total number of participants is 1,000 or more, complete lines (a) and (b):

**a** Enter the percentage of plan assets held as:  
 Public Equity: \_\_\_\_\_% Private Equity: \_\_\_\_\_% Investment-Grade Debt and Interest Rate Hedging Assets: \_\_\_\_\_%  
 High-Yield Debt: \_\_\_\_\_% Real Assets: \_\_\_\_\_% Cash or Cash Equivalents: \_\_\_\_\_% Other: \_\_\_\_\_%

**b** Provide the average duration of the Investment-Grade Debt and Interest Rate Hedging Assets:  
 0-5 years  5-10 years  10-15 years  15 years or more

**20 PBGC missed contribution reporting requirements.** If this is a multiemployer plan or a single-employer plan that is not covered by PBGC, skip line 20.

**a** Is the amount of unpaid minimum required contributions for all years from Schedule SB (Form 5500) line 40 greater than zero?  Yes  No

**b** If line 20a is "Yes," has PBGC been notified as required by ERISA sections 4043(c)(5) and/or 303(k)(4)? Check the applicable box:  
 Yes.  
 No. Reporting was waived under 29 CFR 4043.25(c)(2) because contributions equal to or exceeding the unpaid minimum required contribution were made by the 30th day after the due date.  
 No. The 30-day period referenced in 29 CFR 4043.25(c)(2) has not yet ended, and the sponsor intends to make a contribution equal to or exceeding the unpaid minimum required contribution by the 30th day after the due date.  
 No. Other. Provide explanation.....

**Part VII IRS Compliance Questions**

**21a** Does the plan satisfy the coverage and nondiscrimination tests of Code sections 410(b) and 401(a)(4) by combining this plan with any other plans under the permissive aggregation rules?  Yes  No

**21b** If this is a Code section 401(k) plan, check all boxes that apply to indicate how the plan is intended to satisfy the nondiscrimination requirements for employee deferrals and employer matching contributions (as applicable) under Code sections 401(k)(3) and 401(m)(2).  
 Design-based safe harbor method  
 "Prior year" ADP test  
 "Current year" ADP test  
 N/A

**22** If the plan sponsor is an adopter of a pre-approved plan that received a favorable IRS Opinion Letter, enter the date of the Opinion Letter \_\_\_/\_\_\_/\_\_\_ (MM/DD/YYYY) and the Opinion Letter serial number \_\_\_\_\_.

**ASTRAZENECA DEFINED BENEFIT PENSION PLAN**

Financial Statements

December 31, 2023 and 2022

**ASTRAZENECA DEFINED BENEFIT PENSION PLAN**

Table of Contents

December 31, 2023 and 2022

---

	<u>Page(s)</u>
Report of Independent Auditors	1 - 3
Financial Statements:	
Statements of Net Assets Available for Benefits	4
Statements of Changes in Net Assets Available for Benefits	5
Notes to Financial Statements	6 - 22



## **Report of Independent Auditors**

To the Administrator of AstraZeneca Defined Benefit Pension Plan

### ***Scope and Nature of the ERISA Section 103(a)(3)(C) Audit***

We have performed an audit of the accompanying financial statements of AstraZeneca Defined Benefit Pension Plan (the "Plan"), an employee benefit plan subject to the Employee Retirement Income Security Act of 1974 (ERISA), as permitted by ERISA Section 103(a)(3)(C) (ERISA Section 103(a)(3)(C) audit). The financial statements comprise the statement of net assets available for benefits (in liquidation) as of December 31, 2023, the related statement of changes in net assets available for benefits (in liquidation) for the period from May 17, 2023 to December 31, 2023, the statement of changes in net assets available for benefits (ongoing) for the period from January 1, 2023 to May 16, 2023, the statement of net assets available for benefits (ongoing) as of December 31, 2022, and the related statement of changes in net assets available for benefits (ongoing) for the year then ended, including the related notes (collectively referred to as the "financial statements").

Management, having determined it is permissible in the circumstances, has elected to have the audit of the Plan's financial statements performed in accordance with ERISA Section 103(a)(3)(C) pursuant to 29 CFR 2520.103-8 of the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA. As permitted by ERISA Section 103(a)(3)(C), our audit need not extend to any statements or information related to assets held for investment of the plan (investment information) by a bank or similar institution or insurance carrier that is regulated, supervised, and subject to periodic examination by a state or federal agency, provided that the statements or information regarding assets so held are prepared and certified to by the bank or similar institution or insurance carrier in accordance with 29 CFR 2520.103-5 of the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA (qualified institution).

Management has obtained a certification from a qualified institution as of December 31, 2023 and 2022 and for the periods from June 1, 2023 to December 31, 2023 and from January 1, 2023 to May 31, 2023, stating that the certified investment information, as described in Note 7 to the financial statements, is complete and accurate.

### ***Opinion***

In our opinion, based on our audit and on the procedures performed as described in the Auditors' Responsibilities for the Audit of the Financial Statements section of our report

- the amounts and disclosures in the accompanying financial statements, other than those agreed to or derived from the certified investment information, are presented fairly, in all material respects, in accordance with accounting principles generally accepted in the United States of America.
- the information in the accompanying financial statements related to assets held by and certified to by a qualified institution agrees to, or is derived from, in all material respects, the information prepared and certified by an institution that management determined meets the requirements of ERISA Section 103(a)(3)(C).



### ***Basis for Opinion***

We conducted our audit in accordance with auditing standards generally accepted in the United States of America (US GAAS). Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Plan and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our ERISA Section 103(a)(3)(C) audit opinion.

### ***Basis of Accounting***

As discussed in Note 1 and Note 4 of the financial statements, the AstraZeneca Investment Committee of the Plan's sponsor provided final approval to move forward with termination of the Plan on May 17, 2023, and management determined liquidation to be imminent. As a result, the Plan changed its basis of accounting on May 17, 2023 from the going concern basis to a liquidation basis. Our opinion is not modified with respect to this matter.

### ***Responsibilities of Management for the Financial Statements***

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error. Management's election of the ERISA Section 103(a)(3)(C) audit does not affect management's responsibility for the financial statements.

Management is also responsible for maintaining a current plan instrument, including all plan amendments, administering the plan, and determining that the plan's transactions that are presented and disclosed in the financial statements are in conformity with the plan's provisions, including maintaining sufficient records with respect to each of the participants, to determine the benefits due or which may become due to such participants.

### ***Auditors' Responsibilities for the Audit of the Financial Statements***

Except as described in the Scope and Nature of the ERISA Section 103(a)(3)(C) Audit section of our report, our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with US GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.



In performing an audit in accordance with US GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Plan's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.

Our audit did not extend to the certified investment information, except for obtaining and reading the certification, comparing the certified investment information with the related information presented and disclosed in the financial statements, and reading the disclosures relating to the certified investment information to assess whether they are in accordance with the presentation and disclosure requirements of accounting principles generally accepted in the United States of America.

Accordingly, the objective of an ERISA Section 103(a)(3)(C) audit is not to express an opinion about whether the financial statements as a whole are presented fairly, in all material respects, in accordance with accounting principles generally accepted in the United States of America.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

A handwritten signature in cursive script that reads "PricewaterhouseCoopers LLP".

New York, New York  
October 14, 2024

**ASTRAZENECA DEFINED BENEFIT PENSION PLAN**  
 Statements of Net Assets Available for Benefits  
 December 31, 2023 (In liquidation) and December 31, 2022 (Ongoing)  
*(Dollars in thousands)*

	<b>December 31, 2023 (In liquidation)</b>	<b>December 31, 2022 (Ongoing)</b>
<b>ASSETS</b>		
Investment in the AstraZeneca Master Trust for the Defined Benefit Pension Plan ("Master Trust"), at fair value	\$ -	\$ 832,761
Net assets available for benefits	\$ -	\$ 832,761

*The accompanying notes are an integral part of the financial statements.*

**ASTRAZENECA DEFINED BENEFIT PENSION PLAN**

Statements of Changes in Net Assets Available for Benefits

Periods from May 17, 2023 to December 31, 2023 (In liquidation), from January 1, 2023  
to May 16, 2023 (Ongoing) and for the year ended December 31, 2022 (Ongoing)

*(Dollars in thousands)*

	<b>Period from May 17, 2023 to December 31, 2023 (In liquidation)</b>	<b>Period from January 1, 2023 to May 16, 2023 (Ongoing)</b>	<b>Year ended December 31, 2022 (Ongoing)</b>
<b>Additions to net assets attributed to:</b>			
Net realized and unrealized appreciation (depreciation) in fair value of investment in the Master Trust	\$ 92	\$ 28,171	\$ (242,445)
Employer Contributions	-	-	-
Total additions	<u>92</u>	<u>28,171</u>	<u>(242,445)</u>
<b>Deductions from net assets attributed to:</b>			
Benefits paid to participants	(13,368)	(169,068)	(116,345)
Group annuity contract payment, net of refunds	(695,589)	-	-
Administrative expenses	-	(1,940)	(4,448)
Total deductions	<u>(708,957)</u>	<u>(171,008)</u>	<u>(120,793)</u>
Net decrease	(708,865)	(142,837)	(363,238)
Plan assets transferred (See Note 4)	(3,785)	-	-
Net assets available for benefits:			
Beginning of period (See Note 4)	712,650	832,761	1,195,999
End of period	<u>\$ -</u>	<u>\$ 689,924</u>	<u>\$ 832,761</u>

*The accompanying notes are an integral part of the financial statements.*

# ASTRAZENECA DEFINED BENEFIT PENSION PLAN

Notes to Financial Statements

December 31, 2023 and 2022

## 1. Description of the Plan

The following description of the AstraZeneca Defined Benefit Pension Plan (the “Plan”) provides only general information. Participants should refer to the plan document for a more complete description of the Plan.

### General

The Plan, formerly known as the Zeneca Pension Plan (“Zeneca Pension Plan”) was a qualified defined benefit plan covering retirees of Zeneca Inc. (“Zeneca”) and its subsidiaries, certain employees of AstraZeneca Pharmaceuticals LP (“AZPLP” or the “Sponsor”), certain employees of AstraZeneca LP (“AZLP”), and certain participants formerly covered under the AstraZeneca LP Pension Plan (“AMI”).

Effective December 31, 2001, the AMI Plan was merged into the Zeneca Pension Plan, and the Zeneca Pension Plan was renamed the AstraZeneca Defined Benefit Pension Plan, and sponsorship of the Plan was transferred from Zeneca Holdings Inc. to AZPLP.

The AstraZeneca Investment Committee (“AZIC”) was the Plan's named fiduciary for investment and certain administrative duties, and the AstraZeneca Administration Committee was the Plan's named fiduciary for claims administration and certain other duties. Both committees were appointed by and subject to review by the AstraZeneca North America HR Sub-Committee.

The Plan was amended effective December 31, 2017 to provide that all Plan participants would no longer accrue benefits under the Plan with respect to future service or increased compensation after that date. As such, the accrued benefit of all Plan participants was frozen and fully vested. Furthermore, no employee hired or rehired on or after July 1, 2000 is eligible to participate in the Plan.

On February 27, 2023, the AstraZeneca North America Governance Committee (“NAGC”) approved the termination of the Plan. Effective May 17, 2023, the AZIC selected an insurance company as the new annuity provider of the Plan, which finalized the termination of the Plan. See Plan Termination Note 4 for additional information.

### Administrative Expenses

All costs and expenses incident to the administration and management of the Plan – including compensation of the trustee and investment manager, adviser fees, actuarial fees, legal fees, and Pension Benefit Guaranty Corporation (“PBGC”) premiums – were paid by the Plan and/or the participating employers in the Plan.

### Pension Benefits

The Plan was a noncontributory defined benefit pension plan for employees at covered locations of any entity of which 80% or more of the equity is owned by AZPLP or its affiliates and which has adopted the Plan.

1. Participants obtained nonforfeitable eligibility to receive a pension from the Plan after completion of five years of service. In general, benefits were payable upon attainment of normal retirement age (65); however, provision for early retirement was also included. To participants in Rider 1 (former Zeneca Pension Plan) of the Plan, these benefits were computed as follows:

## ASTRAZENECA DEFINED BENEFIT PENSION PLAN

Notes to Financial Statements

December 31, 2023 and 2022

### 1. Description of the Plan, continued

#### Pension Benefits, continued

- (a) For participants who separated from service on or before February 28, 1998 or for those participants who (i) were employees as of February 28, 1998 and (ii) elected effective as of May 1, 1998 to remain under Schedule A, the annual benefit payable at normal retirement age is equal to the greater of the benefits computed by (i) and (ii) below:
  - (i) Formula A – 1.2% of the highest consecutive three-year average compensation during the participant’s final ten years of employment (“Average Compensation”), multiplied by number of years of credited service (as defined)
  - (ii) Formula B – 1.6% of the Average Compensation multiplied by number of years of service up to a maximum of 50% of the Average Compensation, less 1.6% of the annualized amount that the plan administrator determines is payable to a participant under the federal Social Security Act at the earliest Social Security retirement age upon the date the participant terminates, retires, is discharged, or dies, multiplied by the number of years of service up to a maximum of 50% of a participant’s Primary Insurance Amount
- (b) For those participants in which the service commencement date or rehire date occurs after February 28, 1998, or for those regular or part-time participants who (i) were employees as of February 28, 1998 and (ii) elected to participate in Schedule B as of May 1, 1998, the annual benefit payable at normal retirement age is equal to the sum of (i) and (ii) below:
  - (i) annual benefit computed under paragraph (a) above, for plan years beginning prior to 1998 (see Benefit Schedule B, paragraph 2.1 of the plan document for further date restrictions)
  - (ii) the sum of 1.2% of annual compensation up to \$85,000 (as adjusted for inflation as of the first day of each plan year) and 1.6% of annual compensation above \$85,000 (or adjusted) for each plan year, excluding plan years beginning prior to 1998. For the plan year ended December 31, 2017, the annual compensation break-point was \$85,000.
- (c) Annual benefits for participants who separated from service prior to January 1, 1985 were computed on the basis of the plan formula that was in effect on the date of separation from service.
- (d) The Plan provides for subsidized early retirement as early as age 50 with 20 years of service. For the employee electing early retirement, the benefit was reduced according to a table of factors that takes into consideration age and years of service. A separate reduction schedule based solely on age was used for a participant who terminates employment prior to becoming eligible for early retirement.

## ASTRAZENECA DEFINED BENEFIT PENSION PLAN

Notes to Financial Statements

December 31, 2023 and 2022

### 1. Description of the Plan, continued

#### Pension Benefits, continued

- (e) The normal form of payment under the Plan for married participants was the qualified joint and one-half survivor annuity unless the participant elected an alternate method of payment provided in the Plan and obtained spousal consent. For single participants, the normal form of payment was a single-life annuity.
  - (f) Participants (other than a participant covered under Benefit Schedule B, with at least 15 years of service as of the date of separation) who became permanently disabled were eligible for a disability retirement benefit computed as of the date disability commenced in accordance with the Plan. Participants with service commencement dates starting after February 28, 1998 were not eligible for disability retirement benefits.
2. In general, benefits payable upon normal retirement age (65) to participants in Rider 2 (former AMI Plan) of the Plan are computed as follows:
- (a) All non-collectively bargained employees of AZPLP/AZLP with five or more years of combined vesting service, as defined, with Merck & Co., Inc. (“Merck”) and AZPLP/AZLP (including AMI prior to July 1, 1998) were entitled to monthly pension benefits beginning at normal retirement age (65) equal to the greater of either (i) or (ii) below:
    - (i) 1.8% (2% prior to July 1, 1996) of the average of their highest 5 consecutive calendar years of pay during the last 10 calendar years for each year of credited service, as defined, to 35 years of credited services, less 1.6% of their estimated Social Security benefit for each year of credited service, as defined (up to a maximum of 50% of Social Security benefits), less any benefit payable under the Retirement Plan for Salaried Employees of Merck & Co. (“Merck Plan”) for employees who transferred from Merck on January 1, 1995
    - (ii) \$420 for each year of credited service, as defined, less any benefit payable under the Merck Plan for employees who transferred from Merck on January 1, 1995
  - (b) Transferred employees from Merck with five or more years of vesting service, as defined, as of December 31, 1994, or who subsequently attain five years of combined vesting service, as defined, for Merck and AZPLP/AZLP (including AMI prior to July 1, 1998) were treated as terminated vested employees of the Merck Plan. As such, the benefits beginning at age 65 (normal retirement age) payable under the Merck Plan for the transferred employees were calculated as 2% of the average of their highest five consecutive calendar years of pay during the ten calendar years preceding January 1, 1995, for each year of credited service, as defined, as of December 31, 1994, less 1.6% of the estimated Social Security benefit for each year of credited service, as defined, as of December 31, 1994 (up to a maximum of 50% of the estimated Social Security benefit).

## ASTRAZENECA DEFINED BENEFIT PENSION PLAN

Notes to Financial Statements

December 31, 2023 and 2022

### 1. Description of the Plan, continued

#### Pension Benefits, continued

- (c) Early retirement was allowed between ages 55 and 64, with at least ten years of service. Employees forfeit the right to receive any portion of their accumulated plan benefits if they terminate before rendering five years of vesting service, as defined. The normal form of payment under the Plan for married participants was the qualified joint and one-half survivor annuity unless the participant elected an alternate method of payment provided in the Plan and obtained spousal consent. For single participants, the normal form of payment was a single-life annuity.
3. If an active employee died, then a death benefit was paid to the employee's spouse, if married, or estate, if single, equal to the value of 50% of the early retirement pension the employee would have received had the employee retired and elected a 50% joint and survivor pension immediately prior to death. Active employees who become totally disabled continue to accrue years of service. Upon normal retirement age, disabled employees began receiving normal retirement benefits computed as though they had been employed to normal retirement age with their annual compensation remaining the same as at the time they became disabled.
4. Effective December 19, 2008, the AstraZeneca North America HR Sub-Committee amended the Plan to offer a lump sum optional form of benefit to legacy Zeneca participants who commenced receiving benefits under the Plan on or after January 1, 2009. In addition, the AstraZeneca North America HR Sub-Committee approved extending a one-time opportunity on or prior to July 1, 2009, as established by the Sponsor, to legacy Zeneca participants who were alive as of January 1, 2009 (and their surviving beneficiaries) and who commenced receipt of their benefit under the Plan on or after January 1, 2008 but before January 1, 2009, to convert their current form of benefit payment to a lump sum payment.
5. Effective October 1, 2012, the AstraZeneca North America HR Sub-Committee amended the Plan to define the mortality table and interest rate to be used for purposes of present value benefit determinations. The interest rate was separately defined for distributions, as specified, commencing on and after October 1, 2012, but no later than September 30, 2013, and all distributions commencing after September 30, 2013. In addition, participants (and their surviving spouses) who meet all the requirements, as defined, may have elected to receive their annual retirement benefit prior to reaching their normal retirement date ("Early Distribution Benefit"). The Early Distribution Benefit election must have been made on or before November 30, 2012. The amendment also further defines the determinations for the actuarial equivalence related to the Early Distribution Benefit for various participant groups.
6. Effective January 1, 2017, the Plan was amended to provide additional age and service credit to certain involuntary terminated participants.
7. Effective July 1, 2019, the Plan was amended to change the interest rate to quarterly for purposes of present value benefit determinations.
8. Effective May 4, 2020, the Plan was amended in accordance with the Coronavirus Aid, Relief and Economic Security Act ("CARES Act") with respect to benefit claims and appeals deadlines.

# ASTRAZENECA DEFINED BENEFIT PENSION PLAN

Notes to Financial Statements

December 31, 2023 and 2022

## 2. Summary of Significant Accounting Policies

### Basis of Accounting

The accompanying financial statements as of and for the year ended December 31, 2022 and for the period January 1, 2023 to May 16, 2023 are prepared in conformity with generally accepted accounting principles (“GAAP”) using the going concern (ongoing) basis of accounting. As discussed in Note 4, the Plan terminated. Liquidation of the Plan became imminent on May 17, 2023, when the AZIC selected an insurance company as the new annuity provider of the Plan, which finalized the termination of the Plan. As a result, the Plan changed its basis of accounting as of May 17, 2023 and for the period May 17, 2023 to December 31, 2023 to the liquidation basis in accordance with GAAP.

### Investment Valuation and Income Recognition

Investments were reported at fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The AZIC determined the Plan’s valuation policies utilizing information provided by the investment advisers and custodians. The net investment income and investment expenses of the Plan and appreciation or depreciation in fair value of plan assets represent an allocation based upon the ratio of the Plan’s assets to total Master Trust assets. During the periods ended December 31, 2023 and 2022, the Plan’s assets represented 100% of the assets in the Master Trust, and therefore, no allocations were required. See Note 9 for discussion of fair value measurements.

Purchases and sales of securities were recorded on a trade-date basis. Interest income was recorded on the accrual basis. Dividends were recorded on the ex-dividend date. Net appreciation (depreciation) included the Plan’s gains and losses on investments bought and sold as well as held during the period.

### Payment of Benefits

Benefit payments are recorded when paid.

### Use of Estimates

The preparation of financial statements in conformity with GAAP requires the Sponsor to make estimates and assumptions that affect the reported amounts of assets, liabilities, and changes therein, disclosure of contingent assets and liabilities, and the actuarial present value of accumulated plan benefits as of the date of the financial statements. Actual results could differ from those estimates.

## 3. Funding Policy

AZPLP contributions were made in amounts actuarially determined by an independent actuary to fund the benefits provided by the Plan which will meet or exceed the annual ERISA minimum funding requirements.

# ASTRAZENECA DEFINED BENEFIT PENSION PLAN

## Notes to Financial Statements

December 31, 2023 and 2022

### 4. Plan Termination

In an action of the AstraZeneca North America Governance Committee (“NAGC”), the NAGC resolved, effective March 31, 2022, to commence the process to terminate the Plan. On February 1, 2022, the Plan was amended and Amendment No. 7 was executed to implement the acts necessary or desirable to terminate the Plan, effective March 31, 2022, in accordance with applicable laws and regulations. The Sponsor filed an Application for Determination for Terminating Plan with the Internal Revenue Service (“IRS”) for a determination as to the tax-qualified status of the Plan at the time of termination. The Plan received a final determination letter response from the IRS on January 12, 2023 stating that the termination of the Plan does not adversely affect its qualification for federal tax purposes. Effective May 17, 2023, the AZIC selected an insurance company as the new annuity provider of the Plan. On May 17, 2023, the Sponsor entered into a single premium group annuity contract and paid \$695,589,000, net of premium refunds, which is reported in the Statement of Changes in Net Assets Available for Benefits. Furthermore, effective July 31, 2023, the Plan was amended and Amendment No. 8 was executed to change the definition of disability under the Plan to facilitate the termination of the Plan.

As a result of the termination of the Plan, the AstraZeneca Savings and Security Plan (“AZSSP”) Amendment No. 2 permitted the Plan’s transfer of \$2,133,000 in excess assets to the AZSSP to be held in a suspense account and treated as AZ Retirement Company Contributions. A portion of these transferred assets must be used each year to comply with the IRS qualified replacement plan requirements. In addition, \$1,652,000 of the premium refund was transferred back to the Sponsor during the plan year.

All participants who are not already receiving annuities were given the opportunity to elect a lump sum payout. Benefit obligations of participants who do not elect a lump sum or who are being paid in an annuity form will be transferred under an annuity contract from a highly rated insurance company that will pay and administer future benefit payments. There will be no change in the benefit earned by Plan participants as a result of these actions.

#### *Reconciliation of Statement of Changes in Net Assets Available for Benefits*

Upon adoption of the liquidation basis of accounting, the Plan recorded the following cumulative effect adjustments to net assets available for benefits as of the date of adoption:

	Amount in thousands
Employer contribution receivable	\$ 26,800
PBGC contribution	(2,950)
Dividend income expected to be earned in liquidation	16
Accrued expenses expected to be incurred in liquidation*	<u>(1,140)</u>
Cumulative effect adjustments for changes in basis of accounting	<u>\$ 22,726</u>

\*Accrued expenses expected to be incurred in liquidation mainly consist of administrative fees for various service providers to the Plan, including investment managers, legal, trustee, etc.

## ASTRAZENECA DEFINED BENEFIT PENSION PLAN

Notes to Financial Statements

December 31, 2023 and 2022

### 5. Present Value of Accumulated Plan Benefits

Accumulated plan benefits are those future periodic payments, including lump-sum distributions, that are attributable under the Plan's provisions to the services participants have rendered including benefits expected to be paid to retired or terminated employees or their beneficiaries, beneficiaries of employees who have died, and present employees or their beneficiaries. The accumulated plan benefits for active participants were based on their estimated average compensation during the three years ending on the date as of which the benefit information is presented (the "valuation date"). Benefits payable under all circumstances (retirement, death, disability, and termination of employment) are included to the extent they are deemed attributable to participant service rendered to the valuation date.

The present value of accumulated plan benefits was determined by the Plan's actuary and is the amount that results from applying actuarial assumptions to adjust the accumulated plan benefits to reflect the time value of money (through discounts for interest) and the probability of payment (by means of decrements such as for death, disability, withdrawal, or retirement) between the valuation date and the expected date of payment. The significant actuarial assumptions used in the valuation as of December 31, 2021 on an ongoing basis were as follows: discount rate – 2.90%; life expectancy of participants – Pri-2012 Mortality Table with white collar adjustment and MP-2021 improvement scale; and retirement age on valuation date – rates vary by age.

The significant actuarial assumptions used in the valuation as of December 31, 2022, December 31, 2023 and for the period from January, 1, 2023 to May 16, 2023 were as follows: discount rate – 4.85%; life expectancy of participants – Pri-2012 Mortality Table with white collar adjustment and MP-2021 improvement scale; and retirement age on valuation date – rates vary by age.

Actuarial present value of accumulated plan benefits was performed at January 1, 2022 and 2023, and there would be no material impact had the valuation been performed at December 31 preceding the respective January 1 valuation date.

The actuarially computed present values of vested and nonvested accumulated plan benefits of the Plan as of December 31, 2023, 2022, and 2021 (dollars in thousands) are as follows:

	December 31, 2023 (In liquidation)	December 31, 2022 (Ongoing)	December 31, 2021 (Ongoing)
Actuarial present value of accumulated plan benefits:			
Vested benefits:			
Participants currently receiving payments	\$ -	\$ 462,012	\$ 622,824
Other participants	-	415,839	560,581
	-	877,851	1,183,405
Nonvested benefits	-	1,809	2,438
	-	-	-
Total present value of accumulated plan benefits	\$ -	\$ 879,660	\$ 1,185,843

## ASTRAZENECA DEFINED BENEFIT PENSION PLAN

Notes to Financial Statements

December 31, 2023 and 2022

### 5. Present Value of Accumulated Plan Benefits, continued

The changes in the actuarial present value of accumulated plan benefits of the Plan as of the periods from May 17, 2023 to December 31, 2023 (In liquidation), from January 1, 2023 to May 16, 2023 (Ongoing), for the year ended December 31, 2022 (Ongoing), and for the year ended December 31, 2021 (Ongoing) (dollars in thousands) are as follows:

	Period from May 17, 2023 to December 31, 2023 (In liquidation)	Period from January 1, 2023 to May 16, 2023 (Ongoing)	Year ended December 31, 2022 (Ongoing)	Year ended December 31, 2021 (Ongoing)
Actuarial present value of accumulated plan benefits as of the beginning of the period	\$ 710,895	\$ 879,660	\$ 1,185,843	\$ 1,197,897
Changes during the year due to:				
Decrease in the discount period	-	-	-	38,347
Interest due to the decrease in discount period	695	14,347	32,715	-
Benefits paid	(711,590)	(170,601)	(116,345)	(141,281)
Assumption changes	-	-	(222,553)	72,627
Actuarial loss	-	-	-	18,253
Net decrease	(710,895)	(156,254)	(306,183)	(12,054)
Present value of accumulated benefits as of the end of the period	\$ -	\$ 723,406	\$ 879,660	\$ 1,185,843

#### *Actuarial present value of accumulated plan benefits*

Upon adoption of the liquidation basis of accounting, the Plan recorded the following cumulative effect adjustment in the actuarial present value of accumulated plan benefits at the beginning of the period as the date of adoption:

Change in actuarial assumptions	\$12,511,000
---------------------------------	--------------

Additionally, in conjunction with the adoption of the liquidation basis of accounting, the Plan changed from using a beginning of year to end of year benefit information date. As a result of the change, accumulated plan benefit information is also reported at December 31, 2021, December 31, 2022 and for the periods January 1, 2023 to May 16, 2023 and May 17, 2023 to December 31, 2023. The change in accounting principle was made in accordance with the liquidation basis of accounting.

# ASTRAZENECA DEFINED BENEFIT PENSION PLAN

## Notes to Financial Statements

December 31, 2023 and 2022

---

### 6. Tax Status

On February 4, 2022, the Plan filed Form 5310, Application for Determination for Terminating Plan to the Internal Revenue Service (“IRS”). In response, the IRS has determined and informed the Sponsor by a letter dated January 12, 2023, that the Plan and related trust were designed in accordance with applicable sections of the Internal Revenue Code (“IRC”). In addition, the IRS indicated that the termination of the Plan does not affect its qualification for federal tax purposes. Although the Plan has been amended since receiving the determination letter, the Plan administrator and the Plan’s tax counsel believe that the Plan was designed, in compliance with the applicable requirements of the IRC and, therefore, believe that the Plan was qualified, and the related trust was tax-exempt. See Plan Termination Note 4 for additional information.

Accounting principles generally accepted in the United States of America require plan management to evaluate tax positions taken by the Plan and recognize a tax liability (or asset) if the Plan has taken an uncertain tax position that more likely than not would not be sustained upon examination by the IRS. Plan management has analyzed the tax positions taken by the Plan and has concluded that as of December 31, 2023 and 2022, there are no uncertain tax positions taken or expected to be taken that would require recognition of a liability (or asset) or disclosure in the financial statements. The Plan is subject to routine audits by taxing jurisdictions; however, there are currently no audits for any tax periods in progress. Plan management believes the Plan is no longer subject to income tax examinations for years prior to 2020.

### 7. Investment Information Certified by Trustee

The plan administrator has elected the method of compliance permitted by 29 CFR 2520.103-8 of the DOL Rules and Regulations for Reporting and Disclosure under ERISA. All investment and investment income related information included in the financial statements have been compiled from statements certified as complete and accurate by the trustee, State Street Bank and Trust Company, in accordance with DOL regulations and are presented in reliance solely upon those certifications. Amounts are certified as of December 31, 2023 and 2022 and for the period from June 1, 2023 to December 31, 2023, the period from January 1, 2023 to May 31, 2023 and for the year ended December 31, 2022.

### 8. Investment in Master Trust

All of the Plan’s investments were in the Master Trust, which was established for the investment of assets of the Plan. The assets of the Master Trust were held by the trustee. At December 31, 2023 and 2022, the Plan’s interest in the net assets of the Master Trust was 100%.

## ASTRAZENECA DEFINED BENEFIT PENSION PLAN

Notes to Financial Statements

December 31, 2023 and 2022

### 8. Investment in Master Trust, continued

The following table presents the fair values of investments and related investment income for the Master Trust as of the periods from May 17, 2023 to December 31, 2023 (In liquidation), from January 1, 2023 to May 16, 2023 (Ongoing) and for the year ended December 31, 2022 (Ongoing) are as follows:

	May 17, 2023 - December 31, 2023 (In liquidation)	January 1, 2023 - May 16, 2023 (Ongoing)	January 1, 2022 - December 31, 2022 (Ongoing)
<i>(Dollars in thousands)</i>			
Investments at fair value:			
Commingled funds	\$ -	\$ -	\$ 205,372
Corporate bonds	-	-	408,391
Government bonds	-	-	201,622
Private equity funds	-	-	2,057
Cash equivalents	-	-	18,191
Other assets and liabilities, net	-	-	(5,550)
Total Master Trust investments	-	-	830,083
Cash	-	-	8,783
Receivables	-	-	19,069
Payables	-	-	(25,174)
Net investments in Master Trust	-	-	832,761
Investment income:			
Net appreciation (depreciation) in fair value of investments	\$ 4,079	\$ 20,476	\$ (276,098)
Interest income (loss)	(1,850)	5,574	28,344
Dividend income (loss)	(2,137)	2,137	5,310
Net realized and unrealized appreciation (depreciation) in fair value of in fair value of investment in Master Trust	\$ 92	\$ 28,187	\$ (242,444)

### 9. Fair Value Measurements

FASB ASC 820, *Fair Value Measurement*, establishes a framework for measuring fair value and enhances disclosures about fair value measurements. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under FASB ASC 820 are described as follows:

## ASTRAZENECA DEFINED BENEFIT PENSION PLAN

Notes to Financial Statements

December 31, 2023 and 2022

### 9. Fair Value Measurements, continued

Level 1: Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Plan has the ability to access.

Level 2: Inputs to the valuation methodology include:

- Quoted prices for similar assets or liabilities in active markets
- Quoted prices for identical or similar assets or liabilities in inactive markets
- Inputs other than quoted prices that are observable for the asset or liability
- Inputs that are derived principally from or corroborated by observable market data by correlation or other means

If the asset or liability has a specified (contractual) term, the level 2 input must be observable for substantially the full term of the asset or liability.

Level 3: Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

The asset's or liability's fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of relevant observable inputs and minimize the use of unobservable inputs.

The following is a description of the valuation methodologies used for assets measured at fair value:

*Corporate and government bonds*: Valued using pricing models maximizing the use of observable inputs for similar securities. This includes basing value on yields currently available on comparable securities of issuers with similar credit ratings. When quoted prices are not available for identical or similar bonds, the bond is valued under a discounted cash flows approach that maximizes observable inputs, such as current yields of similar instruments, but includes adjustments for certain risks that may not be observable, such as credit and liquidity risks or a broker quote if available.

*Mutual funds*: Valued at fair value of shares held by the Plan at year end. The fair value is a quoted price in an active market. The net asset value ("NAV") is based upon the assets owned by the fund, minus its liabilities, and then divided by the number of shares outstanding.

The following is a description of the valuation methodologies used for assets valued at NAV as practical expedient in accordance with the Accounting Standards Update ("ASU") 2015-07:

*Commingled funds*: Valued at the NAV of shares held by the Plan at year end. The NAVs, provided by external investment managers as a practical expedient, are based on quoted prices for the fund's underlying securities (some of which are marketable), estimates, appraisals, assumptions, and methods that are reviewed by management. Refer to the unfunded commitments and the redemption restrictions as presented on pages 20-21.

## ASTRAZENECA DEFINED BENEFIT PENSION PLAN

Notes to Financial Statements

December 31, 2023 and 2022

### 9. Fair Value Measurements, continued

*Private equity funds:* Valued at the NAV of shares held by the Plan at year end. The NAVs, provided by private equity fund managers as a practical expedient, are based on the value of the underlying assets owned by the fund, minus its liabilities, and then divided by the number of shares or units outstanding or multiplied by the Plan's pro rata interest, in the case of non-unitized investments. The private equity fund managers provide financial statements on a quarterly basis, which are used to value the securities based on the Plan's ownership percentage. Refer to the unfunded commitments and the redemption restrictions as presented on pages 20-21.

*Cash equivalents:* Cash equivalents include highly liquid investments with an original maturity of 90 days or less, such as money market funds and repurchase agreements. Money market funds are valued at the NAV of shares held by the Plan at year end. NAV is provided by the trustee and is determined based on the fair value of the underlying assets. The underlying assets include short-term fixed income securities.

*Other assets and liabilities, net:* Other assets and liabilities are represented primarily by derivatives. Other assets and liabilities, that are exchange listed and actively traded, are classified as Level 1 while non-exchange listed but still actively traded assets and liabilities are classified as Level 2. A futures contract is an agreement to buy or sell a security or other asset for a set price on a future date. These contracts are traded on major exchanges and are marked to market daily, thus minimizing counterparty risk. The Plan enters into futures contracts mainly to manage the duration and refine the curve positioning of the fixed income portfolios, thus, allowing the investment managers to achieve the overall investment portfolios' objectives. Credit default swaps are used to either synthetically add or reduce credit risk to an individual issuer or a basket of issuers. Depending on the type of contract, the counterparty risk exposure can be either with the exchange or another counterparty. Credit default swaps are valued using daily underlying yield curves and/or credit curves and spreads based upon broker/dealer/index sources, the present value of expected cash flows, and the frequency of which they compound and pay including a weighted default calculation. The Trust actively manages risk by periodically investing in interest rate swaps and fixed income options. Interest rate swaps are used to manage interest rate risk and provide an effective means to adjust portfolio duration, term-structure and maturity mix. Fixed income options are used in numerous ways including: to serve as a hedge, to capitalize on anticipated changes in market volatility, and to focus on income generation. The Trust also enters into forward foreign exchange contracts to hedge against adverse changes in foreign exchange rates related to non-US dollar denominated investments. The Trust is exposed to credit risk for non-performance by the counterparty and to market risk for changes in interest and currency rates.

The preceding methods described may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, although the Plan believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

**ASTRAZENECA DEFINED BENEFIT PENSION PLAN**

Notes to Financial Statements

December 31, 2023 and 2022

9. Fair Value Measurements, continued

The following table lists the fair values of investments as of December 31, 2022 (in thousands):

	<b>Fair Value Measurements Using Input Levels:</b>			
	<b>Level 1</b>	<b>Level 2</b>	<b>Level 3</b>	<b>Fair Value</b>
Cash equivalents	\$ 18,191	\$ -	\$ -	\$ 18,191
Corporate bonds	-	408,391	-	408,391
Government bonds	-	201,622	-	201,622
Other assets and liabilities, net	(989)	(4,561)	-	(5,550)
Total assets in the fair value hierarchy	17,202	605,452	-	622,654
Investments measured at net asset value <i>(a)</i>	-	-	-	207,429
Total Master Trust Investments	\$ 17,202	\$ 605,452	\$ -	\$ 830,083

*(a)* In accordance with Subtopic 820-10, commingled funds and private equity funds that were measured at net asset value per share (or its equivalent) have not been classified in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the line items presented in the statements of net assets available for benefits.

The availability of observable market data is monitored to assess the appropriate classification of financial instruments within the fair value hierarchy. Changes in economic conditions or model-based valuation techniques may require the transfer of financial instruments from one fair value level to another.

For the period from January 1, 2023 to May 16, 2023, from May 17, 2023 to December 31, 2023, and for the year ended December 31, 2022, there were no transfers in or out of levels 1, 2, or 3.

Fair Value of Investments that Calculate Net Asset Value

The following table summarizes investments measured at fair value based on net asset value (NAV) per share as of December 31, 2022 (in thousands).

**ASTRAZENECA DEFINED BENEFIT PENSION PLAN**

Notes to Financial Statements

December 31, 2023 and 2022

9. Fair Value Measurements, continued

Fair Value of Investments that Calculate Net Asset Value, continued

	<b>Fair Value at 12/31/2022 (in thousands)</b>	<b>Unfunded Commitments (in thousands)</b>	<b>Redemption Frequency</b>	<b>Redemption Notice Period</b>
<i>Commingled funds</i>				
PIMCO Investment Grade Credit Bond Portfolio (a)	\$22,835	N/A	Daily	(a)
PIMCO Long Duration Corporate Bond Portfolio (b)	\$73,305	N/A	Daily	(b)
PIMCO Asset-Backed Securities Portfolio (c)	\$4,073	N/A	Daily	(c)
PIMCO Short-Term Floating NAV Portfolio II (d)	\$105,159	N/A	Daily	(d)
<i>Private equity funds</i>				
DCM Private Equity Fund II, LLC (e)	\$1,121	\$0 at 12/31/2023 and \$1,188 at 12/31/2022	N/A	N/A
OCM Asia Principal Opportunities Fund, L.P. (f)	\$23	None	N/A	N/A
Summit Partners Private Equity Fund VII-B, L.P. (g)	\$912	None	N/A	N/A

## ASTRAZENECA DEFINED BENEFIT PENSION PLAN

Notes to Financial Statements

December 31, 2023 and 2022

### 9. Fair Value Measurements, continued

#### Fair Value of Investments that Calculate Net Asset Value, continued

(a) **PIMCO Investment Grade Credit Bond Portfolio** – The Fund seeks maximum total return, consistent with preservation of capital and prudent investment management, by investing under normal circumstances at least 80% of its assets in a diversified portfolio of investment grade fixed income securities of varying maturities, which may be represented by forwards or derivatives such as options, futures contracts, or swap agreements. Assets not invested in investment grade fixed income securities may be invested in other types of Fixed Income Instruments. “Fixed Income Instruments” include bonds, debt securities, and other similar instruments issued by various U.S. and non-U.S. public- or private-sector entities. The account is designed to provide a hedge for AstraZeneca’s U.S. pension liabilities which also have a duration approximately equal to the duration of the portfolio benchmark. The redemption frequency is daily and there is no contractual notice period for redemptions, however, as much advance notice as possible is appreciated.

(b) **PIMCO Long Duration Corporate Bond Portfolio** - The investment objective of the fund is to seek maximum total return, consistent with prudent investment management, by investing under normal circumstances at least 80% of its assets in a portfolio of corporate fixed income instruments, which may be represented by forwards or derivatives such as options, futures contracts or swap agreements. “Fixed Income Instruments” include bonds, debt securities and other similar instruments issued by various U.S. and non-U.S. public or private sector entities. Portfolio strategies may change from time to time. The account is designed to provide a hedge for AstraZeneca’s U.S. pension liabilities which also have a duration approximately equal to the duration of the portfolio benchmark. The redemption frequency is daily and there is no contractual notice period for redemptions, however, as much advance notice as possible is appreciated.

(c) **PIMCO Asset-Backed Securities Portfolio**—The fund seeks maximum total return, consistent with prudent investment management, by investing under normal circumstances at least 80% of its assets in a portfolio of asset-backed securities (“ABS”), of varying maturities, which may be represented by options, futures contracts, or swap agreements. Assets not invested in ABS may be invested in other types of fixed income instruments, which includes bonds, debt securities, and other similar instruments issued by various U.S. and non-U.S. public or private sector entities. Generally, such investments will be used to cover forward exposure and have an aggregate duration that normally will not exceed one year. The account is designed to provide a hedge for AstraZeneca’s U.S. pension liabilities which also have a duration approximately equal to the duration of the portfolio benchmark. The redemption frequency is daily and there is no contractual notice period for redemptions, however, as much advance notice as possible is appreciated.

(d) **PIMCO Short-Term Floating NAV Portfolio II**—The fund seeks maximum current income, consistent with preservation of capital and daily liquidity, by investing under normal circumstances at least 65% of its total assets in a diversified portfolio of fixed income instruments of varying maturities, which may be represented by forwards. “Fixed income instruments” include bonds, debt securities and other similar instruments issued by various U.S. and non-U.S. public or private sector entities. Portfolio strategies may change from time to time. The account is designed to provide a hedge for AstraZeneca’s U.S. pension liabilities which also have a duration approximately equal to the duration of the portfolio benchmark. The redemption frequency is daily and there is no contractual notice period for redemptions, however, as much advance notice as possible is appreciated.

## ASTRAZENECA DEFINED BENEFIT PENSION PLAN

Notes to Financial Statements

December 31, 2023 and 2022

### 9. Fair Value Measurements, continued

#### Fair Value of Investments that Calculate Net Asset Value, continued

(e) **DCM Private Equity Fund II, LLC** – The investment objective of the fund is to invest in private equity partnerships, co-investment entities, and secondary investments, as defined in its operating agreement, in order to provide capital appreciation to members. The fund shall continue until the later of (a) the 12<sup>th</sup> anniversary of the initial closing date and (b) one year after the date on which all investments of the fund have been liquidated, subject to the manager’s right to extend the term for up to two one-year periods with the approval of majority interest, unless sooner terminated as provided in the agreement or by operation of law.

(f) **OCM Asia Principal Opportunities Fund, L.P.** – The primary objective of the fund is to achieve long-term capital appreciation primarily through investments in equity and debt obligations of companies which are undervalued. The fund invests in publicly traded or privately placed equity and debt securities and other obligations such as bridge financings, bank loans and participations, equipment trust certificates and trade credits, equity securities and options and warrants. The fund’s amended and restated limited partnership agreement, dated May 10, 2006, was entered into among OCM Asia Principal Opportunities Fund GP, L.P. as general partner and the limited partners of the Fund. As of December 31, 2020, 100% of committed capital has been drawn down.

(g) **Summit Partners Private Equity Fund VII-B, L.P.** – The investment objective of the fund is to invest in securities of emerging growth companies seeking capital for expansion, including buyout or recapitalization transactions and other related investing activities. The partnership agreement was amended several times to extend the term of the partnership through February 8, 2019 through February 8, 2021. Furthermore, on February 9, 2021, the partnership agreement was amended to extend the term of the partnership for an additional year through February 8, 2022.

### 10. Derivatives

Presented in the following table is the fair value of derivatives within the Master Trust as of December 31, 2022. The net unrealized appreciation (depreciation) of these derivative instruments is included in Investment in the AstraZeneca Master Trust for the Defined Benefit Pension Plan (“Master Trust”), at fair value in the Statements of Net Assets Available for Benefits.

	<b>Fair Value of Derivatives</b>
	<b>(in thousands)</b>
	<b>2022</b>
Forward Foreign Exchange Contract	\$ (37)
Futures	(989)
Interest Rate Swaps	(2,004)
Credit Default Swaps	88
Options	(2,607)

## ASTRAZENECA DEFINED BENEFIT PENSION PLAN

Notes to Financial Statements

December 31, 2023 and 2022

### 10. Derivatives, continued

The following table provides information on the investment gains (losses) on derivatives within the Master Trust for the year ended December 31, 2022. The amounts are included in the Plan's Net realized and unrealized appreciation (depreciation) in fair value of investment in the Master Trust on the Statements of Changes in Net Assets Available for Benefits.

	2022 (in thousands)	
	Realized (Loss) Gain	Unrealized (Loss) Gain
Forward Foreign Exchange Contract	\$ -	\$ (667)
Futures	(38,893)	(372)
Interest Rate Swaps	(1,318)	(2,039)
Credit Default Swaps	(973)	(1,671)
Options	(637)	(2,012)

### 11. Party-in-Interest Transaction

Certain Master Trust investments are shares of short-term investment funds managed by an affiliate of State Street Bank and Trust Company, the trustee of the Plan, and therefore, these transactions qualify as party-in-interest transactions.

### 12. Risks and Uncertainties

The Plan invested in various investment securities through the Master Trust. Investment securities were exposed to various risks such as interest rate, market, and credit risks. Due to the level of risk associated with certain investment securities, it was at least reasonably possible that changes in the values of investment securities could occur in the near term and that such changes could materially affect the amounts reported in the statements of net assets available for benefits.

Plan contributions were made and the actuarial present value of accumulated plan benefits were reported based on certain assumptions pertaining to interest rates, inflation rates and employee demographics, all of which were subject to change. Due to uncertainties inherent in the estimations and assumptions process, it was at least reasonably possible that changes in these estimates and assumptions in the near term would be material to the financial statements.

### 13. Subsequent Events

The Plan has evaluated subsequent events through October 14, 2024, the date the financial statements were available to be issued, for possible adjustments or disclosures in the financial statements.